Spero Therapeutics reports Q4 net income of $26.8M; GSK deal provides $66M upfront

Spero Therapeutics, Inc.

Q4 2022 net income $26.8M ($0.55 EPS) vs net loss $29.2M in Q4 2021; full-year net loss $46.4M ($1.23 loss per share).
Total revenue Q4 2022 $47.4M (up from $2.7M) driven by $46.1M collaboration revenue from GSK and Pfizer deals.
Cash and equivalents $109.1M as of Dec 31, 2022; company expects runway beyond 2024.
Initiated Phase 2 trial of SPR720 in NTM-PD; top-line data expected in first half of 2024.
GSK license for tebipenem HBr: $66M upfront, $9M equity investment, up to $525M milestones plus tiered royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Spero Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, Spero Therapeutics, Inc. (the "Company") issued a press release announcing its results for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-085566

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.